Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis.
Hirano, I; Dellon, ES; Hamilton, JD; Collins, MH; Peterson, K; Chehade, M; Schoepfer, AM; Safroneeva, E; Rothenberg, ME; Falk, GW; et al.
Gastroenterology.
2020;
158:111-122.e10.
Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response.
Haberman, Y; Karns, R; Dexheimer, PJ; Schirmer, M; Somekh, J; Jurickova, I; Braun, T; Novak, E; Bauman, L; Collins, MH; et al.
Nature Communications.
2019;
10.
Maintaining outstanding outcomes using response- And biology-based therapy for intermediate-risk neuroblastoma: A report from the children’s oncology group study ANBL0531.
Twist, CJ; Schmidt, ML; Naranjo, A; London, WB; Tenney, SC; Marachelian, A; Shimada, H; Collins, MH; Esiashvili, N; Adkins, ES; et al.
Journal of Clinical Oncology.
2019;
37:3243-3255.
Budesonide Oral Suspension Significantly Improves Eosinophilic Esophagitis Histology Scoring System Results: Analyses from a 12-Week, Phase 2, Randomized, Placebo-controlled Trial.
Collins, MH; Dellon, ES; Katzka, DA; Hirano, I; Williams, J; Lan, L.
American Journal of Surgical Pathology.
2019;
43:1501-1509.
Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): a multicentre inception cohort study.
Hyams, JS; Thomas, SD; Gotman, N; Haberman, Y; Karns, R; Schirmer, M; Mo, A; Mack, DR; Boyle, B; Griffiths, AM; et al.
The Lancet.
2019;
393:1708-1720.
Consortium of Eosinophilic Gastrointestinal Disease Researchers: Advancing the Field of Eosinophilic GI Disorders Through Collaboration Why Was the Consortium of Eosinophilic Gastrointestinal Disease Researchers Established?.
Gupta, SK; Falk, GW; Aceves, SS; Chehade, M; Collins, MH; Dellon, ES; Gonsalves, N; Hirano, I; Mukkuda, VA; Peterson, KA; et al.
Gastroenterology.
2019;
156:838-842.
Safety and Efficacy of Budesonide Oral Suspension Maintenance Therapy in Patients With Eosinophilic Esophagitis.
Dellon, ES; Katzka, DA; Collins, MH; Gupta, SK; Lan, L; Williams, J; Hirano, I.
Clinical Gastroenterology and Hepatology.
2019;
17:666-673.e8.
RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis.
Hirano, I; Collins, MH; Assouline-Dayan, Y; Evans, L; Gupta, S; Schoepfer, AM; Straumann, A; Safroneeva, E; Grimm, M; Smith, H; et al.
Gastroenterology.
2019;
156:592-603.e10.
Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference.
Dellon, ES; Liacouras, CA; Molina-Infante, J; Furuta, GT; Spergel, JM; Zevit, N; Spechler, SJ; Attwood, SE; Straumann, A; Aceves, SS; et al.
Gastroenterology.
2018;
155:1022-1033.e10.
Alignment of parent- and child-reported outcomes and histology in eosinophilic esophagitis across multiple CEGIR sites.
Aceves, SS; King, E; Collins, MH; Yang, G; Capocelli, KE; Abonia, JP; Atkins, D; Bonis, PA; Carpenter, CL; Dellon, ES; et al.
Journal of Allergy and Clinical Immunology.
2018;
142:130-138.e1.